SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:a0c52115-8bb9-469d-9600-0227a5c13d59"
 

Search: onr:"swepub:oai:lup.lub.lu.se:a0c52115-8bb9-469d-9600-0227a5c13d59" > Zileuton added to l...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma

O'Connor, Brian J. (author)
Löfdahl, Claes-Göran (author)
Lund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
Balter, Meyer (author)
show more...
Szczeklik, Andrew (author)
Boulet, Louis-Philippe (author)
Cairns, Charles B. (author)
show less...
 (creator_code:org_t)
Elsevier BV, 2007
2007
English.
In: Respiratory Medicine. - : Elsevier BV. - 1532-3064 .- 0954-6111. ; 101:6, s. 1088-1096
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Objective: To assess the therapeutic effects of oral zileuton tablets combined with low-dose beclomethasone compared to doubling the dose of beclomethasone, in improving lung function and reducing asthma symptoms. Methods: Randomized, active-controt, double-blind, parallel, multi-center study of zileuton (400 or 600mg QID)+200 mu g beclomethasone dipropionate (BDP) BID versus ptacebo+BDP 400pg BID in asthmatics with baseline FEV, percent predicted values between 40% and 80% following a single-blind ICS (BDP 200 mu g BID) 2-week run-in. During the 3-month double-blind treatment period, assessments included safety, daytime and nighttime symptoms, acute asthma exacerbations, beta(2)-agonist use, AM and PM peak expiratory flow (PEF) and FEV1. Results: The addition of a 5-lipoxygenase (5-LO) inhibitor added to a tow-dose of BDP showed no significant difference in FEV1 compared to doubling the dose of BDR FEV1 improved in all 3 treatment groups, with mean increases of 10% with zileuton 600mg QID+BDP 200 mu g BID, 12% with ziteuton 400 mg QID+BDP 200 mu g BID, and 11% with BDP 400 mu g BID by study end. Within each treatment group, there were significant improvements in asthma symptoms and AM and PM PEF compared to baseline. No significant differences were observed between groups with regards to salbutamol use, acute asthma exacerbations, the requirement for oral/parenteral corticosteroids and adverse clinical events. Conclusions: The addition of a 5-LO inhibitor added to low-dose beclomethasone may be an alternative to higher-doses of ICS in patients unable to achieve sufficient asthma control on tow-dose ICS therapy. (c) 2007 Elsevier Ltd. All rights reserved.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)

Keyword

inhibition
5-lipoxygenase
beclomethasone
asthma
zileuton
Ltb(4)

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view